Metronidazol Artesan-Drossapharm

Metronidazole, the active ingredient in Metronidazol Artesan-Drossapharm, is a nitroimidazole antibiotic presented as an oral dosage form for systemic use. It treats a range of anaerobic bacterial and protozoal infections in adults and children as prescribed by a healthcare professional.

GNH USA supplies Metronidazol Artesan-Drossapharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metronidazole is indicated for infections caused by anaerobic bacteria and susceptible protozoa. It is employed across several clinical pathways: - Bacterial vaginosis: eliminates the anaerobic flora responsible for the condition. - Trichomoniasis: eradicates Trichomonas vaginalis, relieving symptoms. - Amoebiasis: treats intestinal infection caused by Entamoeba histolytica. - Giardiasis: clears Giardia lamblia from the gastrointestinal tract. - Anaerobic bacterial infections: manages intra‑abdominal, pelvic, skin and soft‑tissue infections caused by anaerobes. - Clostridioides difficile‑associated diarrhea (adjunct): reduces toxin‑producing bacterial load when used with standard therapy.

Metronidazole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Metallic taste: transient metallic sensation in the mouth. - Headache: occasional mild headache. - Diarrhea: loose stools during therapy. - Abdominal pain: cramping or discomfort. - Loss of appetite: reduced desire to eat.

Serious or Rare Side Effects: - Seizures: rare neurologic events. - Peripheral neuropathy: tingling or numbness in extremities. - Severe allergic reactions: anaphylaxis, rash, or swelling. - Stevens‑Johnson syndrome: severe skin reactions. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Neutropenia: reduced white blood cell count.

Before initiating therapy, consider the following safety measures: - Assess renal function: adjust use in patients with impaired kidney function. - Avoid alcohol: risk of disulfiram‑like reaction. - Monitor for allergic reactions: discontinue if severe rash or swelling occurs. - Use caution in pregnancy: discuss risks with a healthcare provider. - Contraindicated in known hypersensitivity: do not administer to patients with documented allergy to metronidazole. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Metronidazole can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Alcohol: may cause severe flushing, tachycardia, and hypotension. - Warfarin: potentiates anticoagulant effect, increasing bleeding risk. - Lithium: may raise lithium serum concentrations, risking toxicity.

Moderate Interactions (Monitor Closely): - Carbamazepine: may lower metronidazole levels, reducing effectiveness. - Cimetidine: can increase metronidazole plasma concentration. - Phenytoin: may decrease metronidazole exposure, requiring monitoring.